Advantages Low entry pricing: The $180 month one cost makes tirzepatide accessible to people who might not otherwise afford to try it Transparent pricing: No hidden fees, no mandatory memberships, no bundled services inflating the cost Quality formulation: The tirzepatide-glycine-B12 combination follows current best practices for compounded GLP-1 medications Flexible purchasing: Autoship and one-time purchase options accommodate different preferences Cold-chain shipping: Proper cold packs and expedited delivery options protect medication stability Physician oversight: Licensed physician review through Blue Drop Health PLLC for every order Additional products: Longevity options including NAD+, L-Carnitine, and glutathione for patients interested in broader health optimization Disadvantages Rising costs: The price jump from $180 to $545 across six months may surprise patients who focused on the entry price No refunds after approval: Once the physician writes your prescription, your payment is final Limited support: No nutrition coaching, no regular check-ins, no progress tracking tools included Unknown pharmacy partners: Citizen Meds does not publicly identify which compounding pharmacies prepare their medications State coverage unclear: No published list of which states they serve Weekend support limited: Phone support goes to voicemail on weekends 48-hour claim window: Shipping issues must be reported within 48 hours of delivery Regulatory uncertainty: Compounded tirzepatide faces an evolving regulatory landscape that could affect availability Who Citizen Meds is best for Citizen Meds works best for self-directed patients who want affordable access to compounded tirzepatide without paying for coaching, counseling, or other bundled services they do not need
Careful nutritional assessment, hydration and electrolyte replenishment are a priority
Exploring the Potential Impacts and Mechanisms of the Sermorelin and Ipamorelin Blend Potential Impacts and Mechanisms The scientific exploration of peptides continues to expand, with a growing focus on compounds that regulate hormonal activity and support physiological processes
Medicines in use and in development for endometriosis by clinical development stage The pipeline for endometriosis includes 80 candidates in development, of which 46 are repurposed medicines (drugs/biologics) and 34 are new chemical entities
Back Marks, V (30 June 2006) 'Ellis Samols', The Lancet , 368, 360
The FDA is accepting public comments through June 29, 2026
